During the past decade, Cardiovascular Research of Knoxville conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cardiovascular Research of Knoxville" #1 sponsor was "Bayer" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Brigham and Women's Hospital" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cardiovascular Research of Knoxville" #1 collaborator was "Duke Clinical Research Institute" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Cardiovascular Research of Knoxville" are "Cardiovascular Disease" (3 trials), "Acute Myocardial Infarction" (2 trials), "Heart Failure" (2 trials), "Acute Coronary Syndromes" (1 trials) and "Atherosclerotic Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Cardiovascular Research of Knoxville" in a lesser frequency.

Most popular intervention types in "Cardiovascular Research of Knoxville" are "Drug" (10 trials), "Other" (4 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Apixaban" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Acetylsalicylic acid" (1 trials) and "Acetylsalicylic acid placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cardiovascular Research of Knoxville" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Cardiovascular Research of Knoxville". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 4 completed trials in Cardiovascular Research of Knoxville, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Cardiovascular Research of Knoxville, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".